Acrivon Therapeutics, Inc.
ACRV
$2.37
-$0.04-1.66%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.04M | 6.47M | 6.25M | 6.32M | 6.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.69M | 22.65M | 21.66M | 24.95M | 25.14M |
| Operating Income | -19.69M | -22.65M | -21.66M | -24.95M | -25.14M |
| Income Before Tax | -18.23M | -21.01M | -19.68M | -22.83M | -22.44M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.23M | -21.01M | -19.68M | -22.83M | -22.44M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.23M | -21.01M | -19.68M | -22.83M | -22.44M |
| EBIT | -19.69M | -22.65M | -21.66M | -24.95M | -25.14M |
| EBITDA | -19.34M | -22.31M | -21.35M | -24.65M | -24.89M |
| EPS Basic | -0.47 | -0.55 | -0.51 | -0.60 | -0.59 |
| Normalized Basic EPS | -0.30 | -0.34 | -0.32 | -0.39 | -0.37 |
| EPS Diluted | -0.47 | -0.55 | -0.51 | -0.60 | -0.59 |
| Normalized Diluted EPS | -0.30 | -0.34 | -0.32 | -0.39 | -0.37 |
| Average Basic Shares Outstanding | 38.56M | 38.46M | 38.35M | 38.24M | 38.11M |
| Average Diluted Shares Outstanding | 38.56M | 38.46M | 38.35M | 38.24M | 38.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |